Wellness Clinical Research is recognizing Principal Investigator Lucky Flores, MD, for his documented VARSITY study investigator contribution.
The New England Journal of Medicine published the comparative ulcerative colitis trial in September 2019. This WCR announcement looks back at that research contribution, rather than announcing a new study release.
A direct comparison in ulcerative colitis
VARSITY compared vedolizumab with adalimumab over 52 weeks. The study evaluated clinical remission, endoscopic improvement, and corticosteroid-free clinical remission.
The publication reported greater clinical remission and endoscopic improvement with vedolizumab, while the corticosteroid-free remission comparison did not show superiority. The results illustrate why individual endpoints need to be read in context.
Dr. Flores’s documented trial credit
The PubMed publication record includes Lucky Flores in the VARSITY investigator listing. This credit identifies his involvement in the investigator group supporting the trial.
WCR recognizes that published contribution with a clear distinction between investigator collaboration and manuscript authorship.
A publication history that informs study fit
Dr. Flores’s involvement in comparative and placebo-controlled inflammatory bowel disease research forms part of the experience WCR brings to study assessment.
For a new gastroenterology protocol, relevant prior experience is reviewed together with investigator availability, patient access, specialty procedures, and operational requirements. That practical review supports a clearer discussion with sponsors and CROs about site fit.